Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Recursion Pharmaceuticals

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

1 AI Biotech Stock That Just Scored a Major Milestone

1 AI Biotech Stock That Just Scored a Major Milestone

Down over 85% from all-time highs, Recursion Pharmaceuticals is an AI-powered biotech company that aims to accelerate the drug discovery process.

AI Could Power Up These 2 Biotech Stocks

AI Could Power Up These 2 Biotech Stocks

AI is rapidly transforming the healthcare industry. Evolving companies such as Intuitive Surgical and Recursion Pharmaceuticals can capitalize on this opportunity.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Should You Buy the Dip in This AI-Driven Drug Stock?

Down 76% from all-time highs, is this AI-powered drug stock a good buy right now?

3 Small-Cap Stocks Set To Skyrocket

These under-the-radar companies may offer greater long-term rewards.

Nvidia Owns 4 Stocks — One Is Doing Even Better Than It Is

You're doing something right if your company is worth $2.6 trillion like Nvidia. And it's worth looking at the companies Nvidia invests in.

Investors Business Daily

6 Under-the-Radar AI Stocks That Analysts Expect to Rally

Morgan Stanley is betting on these stocks to benefit from the AI megatrend.

inkl

Read news from The Economist, FT, and more,
with one subscription

1 AI Growth Stock With 54% Upside Potential

1 AI Growth Stock With 54% Upside Potential

Shares of Recursion Pharmaceuticals offer solid upside potential, given the company's trailblazing approach to drug discovery leveraging AI. Here’s a closer look at the biotech stock that has garnered investments from both AI chipmaker Nvidia and ARKK fund manager Cathie Wood.

Nvidia Just Invested $76 Million in 1 Cathie Wood Stock

Nvidia Just Invested $76 Million in 1 Cathie Wood Stock

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

Nvidia Just Invested $76 Billion in 1 Cathie Wood Stock

Nvidia Just Invested $76 Billion in 1 Cathie Wood Stock

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

1 Cathie Wood Stock With Over 100% Upside, According to Analysts

1 Cathie Wood Stock With Over 100% Upside, According to Analysts

This biotech stock under $10 is the newest addition to Cathie Wood's flagship ARKK fund - and Wall Street analysts have high hopes for the shares, too.

Recursion Pharmaceuticals Puts Strength on Full Display

Recursion Pharmaceuticals Puts Strength on Full Display

The drug developer's latest capital raise, a $150 million private placement, comes during a difficult market environment.

Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022

Can This Leading Drug Developer Stock Live Up to the Hype?

Can This Leading Drug Developer Stock Live Up to the Hype?

The drug developer aims to build novel maps of biology. What the heck does that mean, exactly?

Get all your
news in one place.

100’s of premium titles.
One news app.

Recursion Pharmaceuticals's Return On Capital Employed Insights

Recursion Pharmaceuticals (NASDAQ:RXRX) brought in sales totaling $2.53 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 36.91%, resulting in a loss of $64.93 million.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

SP Global Market Intelligence

Intuitive Surgical

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

243,693 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play